Østensen Monika, von Esebeck Mathias, Villiger Peter M
Department of Rheumatology and Clinical Immunology/Allergology, University Hospital of Bern, Switzerland.
J Rheumatol. 2007 Jun;34(6):1266-9. Epub 2007 May 15.
To investigate the attitude of patients towards immunosuppressive and biological drugs in relation to reproduction and the outcome of pregnancies exposed to these drugs.
We performed 2 postal surveys in regard to immunosuppressive drugs and reproduction, one in patients with rheumatic disease, the second in Swiss rheumatologists.
Among the 237 female patients and the 189 male patients contacted for the survey, 72% of women and 40% of men returned the questionnaire. Ninety-four women and 47 men had received one or several immunosuppressive or biological agents during the years 2000-2005. Correct advice in regard to drugs and necessary birth control had been given to 84% of women. Advice to men was more inconsistent. One-third of women and 50% of men treated with potentially teratogenic drugs methotrexate (MTX) or leflunomide had not practiced birth control. The surveys of rheumatologists and patients disclosed 66 pregnancies under therapy with immunosuppressive and biological drugs with successful outcomes in 73%. However, 20% of pregnancies in women occurred under treatment with MTX and leflunomide.
Issues regarding drugs and reproduction are not always sufficiently discussed with female and male patients. The increasing use of combination therapies containing MTX necessitates ensuring that advice regarding birth control is followed in order to avoid pregnancies exposed to potentially fetotoxic drugs.
调查患者对免疫抑制药物和生物药物在生殖方面的态度以及暴露于这些药物的妊娠结局。
我们针对免疫抑制药物与生殖进行了两次邮寄调查,一次针对风湿病患者,另一次针对瑞士风湿病学家。
在联系参与调查的237名女性患者和189名男性患者中,72%的女性和40%的男性返回了问卷。在2000年至2005年期间,94名女性和47名男性接受了一种或几种免疫抑制或生物制剂治疗。84%的女性得到了关于药物和必要避孕措施的正确建议。对男性的建议则更不一致。接受潜在致畸药物甲氨蝶呤(MTX)或来氟米特治疗的女性中有三分之一、男性中有50%未采取避孕措施。对风湿病学家和患者的调查显示,有66例妊娠在接受免疫抑制和生物药物治疗,其中73%结局成功。然而,20%的女性妊娠发生在接受MTX和来氟米特治疗期间。
关于药物与生殖的问题,并未总是与女性和男性患者进行充分讨论。含MTX联合疗法的使用日益增加,有必要确保遵循避孕建议,以避免妊娠暴露于潜在的胎儿毒性药物。